ITCI 250117 120.00C (ITCI250117C120000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

ITCI250117C120000

Watchlist

0.00
0.000.00%

15min DelayClose Jan 8 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Express News | Intra-Cellular Therapies Inc - Sandoz to Sell Generic Caplyta From July 1, 2040
Reuters54minutes ago
Intra-Cellular Therapies Settles CAPLYTA (Lumateperone) Patent Litigation With Sandoz
GlobeNewswire56minutes ago
Express News | Intra-Cellular Therapies Settles Caplyta® (Lumateperone) Patent Litigation With Sandoz
Reuters56minutes ago
RBC Capital Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Cuts Target Price to $108
Moomoo NewsJan 7 09:35 ET · Ratings
RBC Trims Price Target on Intra-Cellular Therapies to $108 From $112, Keeps Outperform Rating
MT NewswiresJan 7 07:08 ET · Ratings
Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswireJan 6 08:00 ET

Comments

Tonyco

Oct 9, 2024 22:43

Columns Scribblings of a madman!

Ready for some research results?
Summary: XTNT is really undervalued and oversold. Also, ITCI, I guess. Not LLY though, fuck them.

Meltyy

Apr 1, 2024 02:47

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies (ITCI.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$Hutchmed (China) (HCM.US)$ Phase 3
$Viracta Therapeutics (VIRX.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Marinus Pharmaceuticals (MRNS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3...

Moomoo AI

Mar 27, 2024 10:03

Intra-Cellular Therapies is nearing breakeven, contingent on maintaining a 57% annual growth rate. Its lack of debt, unusual for a pharma company, reduces investment risk.

Market Sentiment Around Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Meltyy

Mar 21, 2024 21:48

Mental Health Biotech Catalyst Watchlist

$Vanda Pharmaceuticals (VNDA.US)$ PDUFA
$Intra-Cellular Therapies (ITCI.US)$ Phase 3
$Bristol-Myers Squibb (BMY.US)$ PDUFA
$Alzamend Neuro (ALZN.US)$ Phase 2
$Alzamend Neuro (ALZN.US)$ Phase 2a

Meltyy

Feb 21, 2024 22:05

Biotech Stock Catalyst Watchlist

🎯 Ph 3 readouts in Q1 2024...
$Pfizer (PFE.US)$ Phase 3
$Palatin Technologies (PTN.US)$ Phase 3
$Annovis Bio (ANVS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Ironwood Pharmaceuticals (IRWD.US)$ Phase 3
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ $Novocure (NVCR.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$...